Research Article - Biomedical Research (2017) Volume 28, Issue 19
Clinical effect of the concomitant administration of bevacizumab with docetaxel, 5-FU, and cisplatin on advanced gastric cancer
Objective: This study aimed to explore the therapeutic effect of bevacizumab concomitantly administered with docetaxel, 5-FU, and cisplatin on patients with advanced gastric cancer.
Methods: A total of 60 patients with advanced gastric cancer were recruited and received the relevant therapy at our hospital over the period of December 2015 to December 2016. All patients were divided into two groups with 30 patients in each group. Patients in the control group received docetaxel, 5-FU, and cisplatin chemotherapy. Patients in the observation group received docetaxel, 5-FU, and cisplatin chemotherapy combined with bevacizumab. Subsequently, the therapeutic effects of the different treatments on the patients in the two groups were compared.
Results: The effective rates of the two clinical treatments were compared. The effective rate of the treatment administered to the observation group was 76.66%, which was higher than that (46.67%) of the treatment administered to the control group. The comparative difference between the two groups was statistically significant (p<0.05). After treatment, the IgA and IgG levels of the patients in the observation group significantly improved relative to those of the patients in the control group (p<0.05). The IgM levels of the patients in the observation group was not significantly different from those of the patients in the control group before and after treatment (p>0.05). The life quality scores of the patients in the observation group were significantly higher than those in the control group, and their comparative difference was statistically significant (p<0.05).
Conclusion: The concomitant application of bevacizumab with docetaxel, 5-FU, and cisplatin chemotherapy exhibited good clinical effect. In addition, the combined treatment improved the life quality of patients with advanced gastric cancer. Therefore, this therapeutic method should be further applied clinically.Author(s): Zhen-Kang Qiu, Wei-Wei Qi, Ning Liu, Li-Bin Sun, Yuan Gao, Guo-Hong Yu, Wen-Sheng Qiu